RCUS FY 2024 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$258M+120.5% YoY

Gross Profit

$258M100.0% margin

Operating Income

-$330M-127.9% margin

Net Income

-$283M-109.7% margin

EPS (Diluted)

$-3.14

Cash Flow

Operating Cash Flow

-$170M

Free Cash Flow

-$176M

Stock-Based Comp.

$76M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$665M

Stockholders' Equity

$485M

Cash & Equivalents

$150M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$258M	$117M	+120.5%
Gross Profit	$258M	$117M	+120.5%
Operating Income	-$330M	-$340M	+2.9%
Net Income	-$283M	-$307M	+7.8%